Tampere, Finland, November 29, 2024 — Combinostics today announced that it has entered an agreement with the Swedish company SyntheticMR where SyntheticMR, subject to approval by an Extraordinary General Meeting, will acquire all shares in Combinostics.
SyntheticMR develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR has developed SyMRI® which delivers multiple adjustable contrast images and quantitative data from a single 5-minute scan. By combining SyntheticMR’s ability to provide brain tissue characterisation and Combinostics’ segmentation algorithms, the two together meet customer demand for a combined capability, particularly related to neurodegenerative diseases such as MS and Dementia.
Combinostics’ business model is primarily based on annual subscriptions and has an established base of ARR customers with high customer satisfaction. This is expected to strengthen the ability of SyntheticMR to pursue plans in the same direction with subscribing customers. This is realised through the platform provided by Combinostics via a cloud solution. Conversely, there are customer groups that require on-site installation and there the companies complement each other as both solutions intend to be delivered on the respective platform.ber
We have identified significant underlying value in Combinostics, which we believe can be realised by, among other things, accelerating sales activity and through the synergies that an acquisition brings within the SyntheticMR group. We believe that the expertise and commitment of the employees within Combinostics are central to Combinostics' success and it is our strong belief that there is good potential to realise Combinostics' underlying value and growth with a common ambition. As part of SyntheticMR, there are very good growth opportunities and we see good opportunities to significantly expand our customer offering already in 2025, as well as generate a significant increase in sales already in the short term. We look forward to continuing to develop Combinostics' offering as part of SyntheticMR and see this as a milestone in our vision to become the leading provider of analysis and imaging methods for magnetic resonance imaging
With Combinostics’ ambition to provide effective decision support, objectivity and thus better patient outcomes, the journey forward with SyntheticMR is seen as a key factor. With quantification of brain characteristics combined with AI-driven statistical analysis, we gain an ability to provide an insight into the state of the brain like no other. We are confident of strong synergies, both organisationally and commercially.
About SyntheticMR
SyntheticMR develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR has developed SyMRI® which delivers multiple adjustable contrast images and quantitative data from a single 5-minute scan. The SyMRI product is available in different packages. SyMRI NEURO delivers multiple contrast images, tissue segmentation and quantitative data about the brain. SyMRI MSK provides multiple contrast images and quantitative data for knee and spine anatomies. SyMRI NEURO is CE marked and FDA 510(k) cleared and SyMRI MSK is CE marked. SyMRI is a registered trademark in Europe and the US. SyntheticMR is listed on the Spotlight Stock Market Exchange in Stockholm, Sweden. For more information, visit www.syntheticmr.com.
About Combinostics
Combinostics’ AI-powered cNeuro suite of products helps clinicians make a difference in the lives of patients with neurological disorders. By quantifying brain images and integrating patient data from multiple sources with insights from previous patients, the company’s unique software tools provide radiologists and clinicians the support they need for confident, evidence-based diagnostic and management decisions. The company was founded in 2014 and is headquartered in Tampere, Finland. For more information, please visit www.combinostics.com.
